mani
immun
therapeut
strategi
develop
melanoma
treat
metastat
diseas
prevent
diseas
reoccurr
howev
human
melanoma
cell
often
defici
antigen
process
appear
play
role
expans
escap
immunosurveil
exampl
express
transport
associ
antigen
process
downregul
mous
melanoma
cell
line
result
lack
tumorassoci
antigen
process
low
surfac
express
mhc
class
molecul
low
immunogen
observ
restor
express
transfect
resurrect
process
present
viral
antigen
melanomaassoci
antigen
immun
irradi
transfect
cell
gener
ctl
capabl
kill
transfect
target
target
defici
furthermor
transfect
grow
significantli
slower
rate
mice
cell
experiment
model
close
recapitul
clinic
situat
treatment
tumor
mice
vaccinia
viru
vector
express
also
significantli
decreas
tumor
growth
vivo
furthermor
tumor
treat
vaccinia
significantli
reduc
number
immunosuppress
posit
tumor
infiltr
lymphocyt
therefor
express
restor
antigen
present
immunogen
melanoma
cell
concomitantli
reduc
immunosuppress
product
local
tumor
site
therebi
increas
immunosurveil
mechan
tumor
wileyliss
inc
melanoma
maa
neoplasm
aris
pigment
melanocyt
differenti
neural
crest
cutan
maa
repres
skin
cancer
account
almost
death
associ
diseas
incid
maa
last
year
doubl
unit
state
new
case
death
intermitt
acut
sun
exposur
lifetim
sun
exposur
age
skin
pigment
type
immun
suppress
atyp
nevi
famili
histori
risk
factor
maa
earli
stage
diseas
curabl
reoccurr
common
later
stage
diseas
prognosi
poor
diseas
spread
lymph
node
tissu
standard
treatment
biopsi
wide
excis
histolog
determin
lesion
malign
case
region
sentinel
lymph
node
also
remov
posit
adjuv
therapi
consist
interferona
may
administ
respons
rate
low
long
term
benefit
signific
howev
case
spontan
remiss
reoccurr
diseas
mani
year
remiss
resect
correl
remiss
immun
cell
infiltr
suggest
immun
surveil
process
could
leverag
develop
treatment
late
stage
diseas
discoveri
tumor
antigen
associ
maa
led
research
develop
therapeut
vaccin
design
gener
antitumor
respons
aim
control
metastasi
wide
varieti
vaccin
approach
protocol
current
test
result
show
even
though
specif
cellular
immun
respons
gener
antigen
respons
diseas
treatment
low
reason
low
respons
rate
thought
low
immunogen
antigen
usual
selfantigen
natur
select
tumor
variant
immunesuppress
phenotyp
aris
process
call
immunoedit
natur
immun
suppress
may
includ
secret
immunosuppress
cytokin
express
ligand
fasl
initi
apoptosi
cytotox
tcell
tumor
variant
defici
antigen
process
present
variant
defici
mhc
class
antigen
process
pathway
express
mhc
class
antigen
cell
surfac
consequ
specif
cytotox
tcell
gener
vaccin
protocol
unabl
recogn
kill
tumor
variant
due
defect
present
tumor
associ
antigenderiv
peptid
recogn
ctl
mhc
class
restrict
antigen
present
pathway
consist
number
gene
encod
mhc
class
locu
human
chromosom
pathway
gener
peptid
endogen
protein
degrad
action
proteolyt
enzym
locat
proteolyt
complex
call
proteasom
peptid
transport
cytoplasm
endoplasm
reticulum
er
abc
transport
transport
associ
antigen
process
tap
heterodim
compos
subunit
within
er
peptid
may
trim
resid
er
proteas
subsequ
load
onto
mhc
class
molecul
consist
mhc
heavi
chain
assembl
complex
aid
number
chaperon
protein
includ
calreticulin
calnexin
respons
fold
mhc
class
heavi
chain
stabil
associ
tapasin
respons
anchor
mhc
molecul
tap
load
peptid
onto
mhc
class
molecul
properli
assembl
complex
transport
cell
surfac
secretori
pathway
cell
surfac
function
mhc
class
molecul
offer
ligand
tcr
tcell
tcr
bind
high
enough
affin
activ
tcell
occur
target
cell
destroy
alter
defici
antigen
present
pathway
lead
variant
give
rise
nonimmunogen
tumor
defici
due
chromosom
lesion
lead
loss
heterozygos
mutat
gene
pathway
refer
hard
lesion
case
howev
defici
mhc
class
antigen
express
cell
surfac
due
soft
lesion
character
downregul
compon
antigen
present
pathway
downregul
critic
factor
mhc
class
antigen
defici
associ
diseas
progress
death
cutan
orbit
maa
convers
express
associ
tumor
infiltr
lymphocyt
til
characterist
good
clinic
outcom
spontan
regress
maa
studi
examin
effect
restor
express
mhc
class
antigen
surfac
express
murin
maa
cell
line
cell
subclon
mous
maa
cell
line
weakli
immunogen
wide
use
tumor
model
tumorhost
immun
interact
tumor
like
metastat
carcinoma
defici
compon
mhc
class
antigenprocess
pathway
includ
tap
mhc
class
antigen
surfac
express
proteasom
subunit
b
chaperon
tapasin
downregul
antigen
present
pathway
revers
ifng
treatment
test
hypothesi
restor
express
cell
increas
mhc
class
antigen
surfac
express
immunogen
make
cell
visibl
immun
surveil
mechan
mous
strain
b
obtain
jackson
laboratori
bar
harbor
maintain
biotechnolog
breed
facil
univers
british
columbia
vancouv
bc
canada
mice
maintain
accord
guidelin
canadian
council
anim
care
mice
kept
standard
diet
water
ad
libitum
coloni
routin
screen
mycoplasma
pulmoni
mycoplasma
arthritidi
rodent
coronavirus
includ
hepat
sendai
viru
use
murin
immunocomb
test
charl
river
laboratori
wilmington
mice
use
experi
week
age
vesicular
stomat
viru
indiana
strain
vsv
gift
frank
tufaro
univers
british
columbia
cultur
vero
cell
american
type
tissu
cultur
atcc
rockvil
md
recombin
vaccinia
viru
vv
either
carri
gene
empti
plasmid
vector
neg
control
describ
previous
vv
strain
grown
cell
atcc
vsv
vv
titr
determin
tissu
cultur
infect
dose
tcid
assay
standard
plaqu
assay
pfu
use
vero
cell
cell
respect
rma
rma
vero
cell
murin
maa
cultur
medium
supplement
heat
inactiv
fetal
bovin
serum
hyclon
logan
ut
lglutamin
mm
penicillin
iuml
streptomycin
lgml
hepe
mm
murin
lung
carcinoma
murin
tapasin
fibroblast
kind
gift
dr
luc
van
kaer
vanderbilt
univers
school
medicin
nashvil
tn
cell
line
cultur
dmem
supplement
clone
rat
vectoronli
transfect
cell
creat
transfect
cell
cdna
mammalian
express
vector
ph
maintain
geneticin
invitrogen
burlington
canada
select
medium
two
clone
design
clone
control
transfect
vector
design
mous
express
cell
cell
examin
immunoblot
total
extract
cell
separ
polyacrylamidesd
gel
blot
onto
nitrocellulos
filter
blot
probe
mous
relev
specif
rabbit
antiserum
dilut
blot
incub
horseradish
peroxidaselabel
antirabbit
igg
antibodi
dilut
immun
complex
visual
enhanc
chemiluminesc
ecl
accord
instruct
manufactur
ge
healthcar
chalfont
st
gile
uk
rabbit
antiserum
mous
protein
creat
immun
rabbit
common
peptid
sequenc
rggcyramvealaapadc
cystein
ctermin
link
keyhol
limpet
hemocyanin
pierc
biotechnolog
rockford
il
specif
antiserum
confirm
detect
band
kda
size
lysat
tapexpress
cell
rma
absent
lysat
fibroblast
deriv
mice
rabbit
serum
mous
rat
kindli
provid
dr
geoff
butcher
univers
cambridg
cambridg
uk
mous
tapasin
express
cell
lyse
lysi
buffer
min
ice
spun
g
min
preclear
protein
gsepharos
ge
healthcar
tapasin
immunoprecipit
rabbit
antitapasin
antiserum
number
courtesi
dr
ted
hansen
washington
univers
school
medicin
st
loui
mo
protein
g
sepharos
follow
separ
sdspage
transfer
pdvf
membran
ge
healthcar
probe
antiserum
follow
ecl
describ
earlier
clone
cell
infect
multipl
infect
moi
incub
day
co
follow
fixat
prepar
fac
analysi
indirect
immunofluoresc
stain
conform
specif
monoclon
antibodi
ab
b
atcc
b
atcc
detect
mhc
class
surfac
express
aliquot
cell
incub
min
primari
ab
b
b
antigen
wash
twice
pb
cell
resuspend
incub
min
fitcconjug
rabbit
antimous
igg
secondari
ab
dakopatt
glostrup
denmark
ia
b
antigen
peconjug
antimous
ia
b
bd
bioscienc
mississauga
canada
use
dilut
stain
cell
min
wash
time
pb
facscan
analyz
becton
dickinson
mountain
view
ca
measur
mean
logarithm
fluoresc
intens
associ
stain
surfac
antigen
splenocyt
cultur
complet
medium
contain
heatinactiv
hyclon
fb
lglutamin
iuml
penicillin
lgml
streptomycin
mm
hepe
mm
nonessenti
amino
acid
mm
napyruv
lm
co
b
antigenrestrict
vsvspecif
ctl
gener
infect
mice
ip
vsv
tcid
splenocyt
harvest
day
infect
cultur
addit
day
media
cellsml
contain
vsvnp
peptid
rgyvyqgl
lgml
co
gener
b
antigenrestrict
tyrosinas
relat
specif
ctl
peptid
vydffvwl
lg
mix
titermax
adjuv
cedarlan
laboratori
hornbi
canada
pb
inject
subcutan
mice
procedur
repeat
day
fourteen
day
initi
inject
mice
receiv
addit
inject
ip
girradi
rma
cell
cell
irradi
rma
cell
prepar
incub
cell
peptid
lgml
peptid
ml
media
overnight
room
temperatur
follow
girradi
rad
cell
wash
resuspend
pb
seventeen
day
initi
inject
immun
spleen
remov
splenocyt
cell
cultur
day
girradi
splenocyt
cell
puls
vydffvwl
peptid
lgml
gener
tumorspecif
ctl
mice
inject
ip
girradi
rad
cell
phb
cell
cellsmous
day
immun
splenocyt
remov
cultur
stimul
stimulatorsplenocyt
ratio
anoth
day
co
stimul
prepar
incub
cell
cell
hr
mitomycin
c
lgml
follow
girradi
rad
wash
time
addit
splenocyt
cultur
cytotox
assay
vsv
specif
tumorspecif
effector
ctl
cytotox
activ
measur
standard
hr
cr
releas
assay
overnight
vsv
moi
infect
cell
provid
target
vsvspecif
ctl
assay
tumorspecif
kill
cell
target
cell
untreat
target
label
na
cell
ge
healthcar
hr
wash
extens
mice
n
inject
subcutan
hindquart
detect
cell
tumor
mass
homogen
pass
nylon
cell
strainer
lm
til
isol
centrifug
ficollpaqu
til
stimul
phorbol
ngml
sigmaaldrich
canada
oakvil
canada
calcium
ionophor
lgml
sigmaaldrich
golgiplug
becton
dickinson
hr
afterward
fcreceptor
stimul
til
block
antimous
bd
bioscienc
min
cell
fix
permeabil
doubl
stain
peconjug
antimous
fitcconjug
antimous
bd
bioscienc
accord
protocol
provid
cytofixcytoperm
plu
kit
bd
bioscienc
final
mean
logarithm
fluoresc
intens
measur
use
facscan
analyz
becton
dickinson
effect
infect
surfac
mhc
class
antigen
express
analyz
use
probabl
bin
chi
test
flowjo
ashland
result
consid
statist
differ
x
valu
greater
impli
distribut
differ
p
confid
effect
rtap
transfect
treatment
vaccinia
vector
growth
tumor
analyz
anova
tukey
hsd
test
use
multipl
comparison
determin
differenti
effect
treatment
tumor
growth
effect
vaccinia
vector
percentag
til
produc
analyz
anova
p
valu
less
correct
multipl
comparison
consid
signific
b
antigen
surfac
express
mhc
class
ii
ia
b
antigen
express
cdna
use
transfect
allow
distinct
polymeras
chain
reaction
endogen
mous
transfect
determin
transfect
effici
clone
stabil
data
shown
mous
mous
tapasin
tpn
protein
express
examin
cell
transfect
immunoblot
rma
cell
use
posit
control
tapasin
express
cell
use
neg
control
express
fibroblast
deriv
tapasin
mice
use
neg
control
mous
tapa
sin
cell
test
mous
tapasin
express
fig
normal
cell
cell
neg
express
mous
tapasin
cell
posit
express
express
also
induc
stabil
express
endogen
mous
cell
express
also
greatli
increas
endogen
level
mous
tapasin
mhc
class
class
ii
antigen
surfac
express
cell
compar
surfac
express
cell
use
fac
analysi
antibodi
use
fac
analysi
conformationspecif
bind
b
b
ia
b
antigen
properli
fold
load
antigen
peptid
cell
exhibit
signific
express
conform
specif
matur
b
b
antigen
cell
surfac
fig
contrast
cell
cell
undetect
level
b
antigen
cell
surfac
small
amount
b
antigen
vectoralon
transfect
cell
exhibit
small
popul
cell
posit
surfac
ia
b
antigen
express
total
popul
howev
popul
neither
increas
decreas
cell
express
compar
untransfect
vectoralon
transfect
cell
test
whether
express
subsequ
increas
antigen
surfac
express
restor
immunogen
tcell
recognit
cell
measur
abil
cell
process
present
b
antigenspecif
immunodomin
vsv
antigen
vsvnp
vsvnp
specif
cytotox
splenocyt
abl
kill
vsvinfect
cell
vsvinfect
cell
cr
releas
assay
fig
cell
abl
correctli
process
present
viral
antigen
cell
also
examin
express
abl
restor
surfac
present
b
antigenrestrict
tumorassoci
antigen
cr
releas
assay
show
cell
sensit
kill
splenocyt
compar
cell
cell
resist
kill
fig
cell
therefor
abl
present
tumorassoci
antigen
context
b
antigen
make
cell
sensit
kill
specif
splenocyt
ctl
assay
measur
immunogen
cell
express
splenocyt
mice
immun
cell
abl
kill
target
cell
line
contrast
splenocyt
mice
immun
cell
possess
diminish
cytotox
activ
fig
experi
demonstr
express
restor
antigen
process
suffici
make
cell
sensit
kill
antigenspecif
cytotox
cell
addit
express
cell
stimul
immun
respons
gener
cytotox
cell
capabl
kill
cell
express
surfac
antigen
also
low
level
antigen
express
infect
cell
either
examin
effect
day
mhc
class
antigen
surfac
express
fac
analysi
demonstr
b
antigen
upregul
p
x
tabl
effect
express
tumor
growth
rate
examin
syngen
mous
model
tap
tumor
grown
hindquart
mice
treat
either
vaccinia
express
vector
vaccinia
vector
control
pb
tumor
growth
rate
analyz
anova
reveal
signific
reduct
tumor
mass
due
effect
rtap
transfect
p
vaccinia
treatment
p
signific
interact
p
howev
main
effect
natur
interact
character
comparison
treatment
group
multipl
comparison
show
growth
rate
tumor
significantli
slow
treatment
p
treatment
hand
tap
tumor
growth
rate
significantli
retard
p
differ
vaccinia
vector
p
fig
express
cytokin
capabl
inhibit
cytotox
tcell
respons
measur
lymphocyt
infiltr
cell
tumor
treat
pb
percentag
til
express
tumor
determin
fac
analysi
treatment
compar
use
anova
fig
tumor
treat
significantli
reduc
lymphocyt
express
compar
p
pb
p
treatment
treatment
tumor
also
significantli
reduc
number
express
lymphocyt
compar
tumor
treat
pb
p
data
repres
fold
increas
mean
fluoresc
intens
cell
fold
increas
cell
subtract
detect
flow
cytometri
use
antibodi
b
b
antigen
restor
antigen
process
mhc
class
antigen
express
immunogen
transfect
infect
alon
maa
cell
occur
despit
numer
defici
antigen
present
pathway
also
demonstr
cell
line
similar
antigen
presentationdefici
phenotyp
murin
nsclc
cell
line
human
maa
human
small
cell
lung
carcinoma
human
squamou
cell
carcinoma
head
neck
human
renal
cell
carcinoma
cell
express
stabil
express
increas
express
endogen
tapasin
indic
reexpress
may
lead
gener
reconstitut
sever
compon
mhc
class
antigenprocess
pathway
may
therefor
increas
amount
antigen
peptid
avail
assembl
onto
mhc
class
molecul
er
restor
tap
express
tapdefici
cancer
cell
make
wide
varieti
peptid
deriv
tumorspecif
associ
antigen
avail
perhap
may
compens
unpredict
defici
cell
mhc
class
antigen
allel
repertoir
case
cell
gene
transfer
abl
resurrect
present
appropri
peptid
b
antigen
allow
ctl
kill
cell
present
b
antigenspecif
peptid
deriv
make
cell
suscept
specif
ctl
lysi
vitro
vivo
vaccin
irradi
cell
express
enhanc
greatli
ctl
activ
toward
target
cell
also
untransfect
target
cell
indic
like
necessari
everi
cell
reexpress
immun
toler
tumor
broken
allow
cytotox
tcell
respons
occur
support
previou
vivo
studi
lung
carcinoma
mice
initi
immun
express
better
abl
reject
challeng
untransfect
unlik
mice
initi
immun
untransfect
perhap
encourag
applic
metastat
diseas
lysi
cell
splenocyt
gener
vaccin
irradi
cell
demonstr
suffici
antigen
surfac
cell
facilit
cytolyt
activ
activ
product
activ
cell
must
transfer
way
dendrit
cell
involv
crosspresent
mhc
class
tumor
antigen
crucial
step
gener
specif
cytotox
tcell
respons
express
cell
result
sourc
antigen
may
bound
mhc
class
antigen
surfac
cell
mhc
class
antigenrestrict
antigen
transfer
dendrit
cell
mhc
class
antigen
altern
dendrit
cell
may
access
process
tumor
antigen
er
compart
cell
intern
antigen
crosspresent
enhanc
immunogen
cell
signific
effect
tumor
growth
mice
vaccin
mice
maa
antigen
specif
b
antigen
protect
tumor
challeng
challeng
cell
tcell
studi
tumor
growth
retard
without
prior
vaccin
tumor
differenti
antigen
though
protect
complet
prior
vaccin
effect
also
appear
transfer
vivo
vaccinia
express
vector
case
express
effect
tumor
growth
also
vector
provid
adjuv
effect
addit
found
vitro
infect
cell
transfect
r
cell
greatli
enhanc
b
b
antigen
surfac
express
rel
infect
cell
may
indic
tap
activ
alreadi
maximum
result
transfect
addit
express
vv
construct
upregul
mhc
class
antigen
express
great
extent
propos
addit
tumor
antigen
upon
infect
tumor
cell
also
present
viral
antigen
presenc
tap
provid
epitop
ctl
recognit
presenc
vv
process
tumor
antigen
dc
may
also
assist
break
toler
immun
system
toward
tumor
cell
act
danger
signal
contribut
prime
tumor
antigenspecif
immun
respons
furthermor
tumor
known
harbor
regulatori
tcell
secret
cytokin
energ
tcell
tumor
gene
transfer
vaccinia
vector
reduc
number
secret
lymphocyt
tumor
one
modul
factor
implic
resist
maa
antitumor
immun
respons
express
conjunct
viral
gene
transfer
vector
promot
type
respons
function
retard
tumor
growth
thu
immunotherapeut
approach
util
tap
potenti
restor
prime
expans
specif
tcell
subsequ
abil
tumor
process
present
tumor
antigen
